The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
NACLC 2022 | Unanswered questions in treating NSCLC with radiotherapy
Puneeth Iyengar, MD, PhD, UT Southwestern Medical Center, Dallas, TX, describes outstanding issues in utilizing radiotherapy in non-small cell lung cancer (NSCLC), which has limited efficacy in oligometastatic NSCLC. Elucidating predicative and prognostic biomarkers are necessary to enhance outcomes in this subset of patients, as well as finding the right time to administer radiotherapy. Dr Iyengar additionally comments on dosing strategies and the role of measuring progression-free survival (PFS) and circulating tumor DNA (ctDNA). This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Puneeth Iyengar, MD, PhD, has received honoraria from Astrazeneca and Incyte.
